### ANNUAL BURDEN ESTIMATES—Continued

| Instrument                                | Number of respondents | Number of responses per respondent | Average burden<br>hours per<br>response | Total burden hours |
|---|-----------------------|------------------------------------|---|--------------------|
| Federal Tax Offset contact                | 54                    | 1                                  | 2 minutes                               | 1.8 hours.         |
| Update Spec                               | 54                    | 1                                  | 2 minutes                               | 1.8 hours.         |
| Issuance of pre-offset notice             | 54                    | 1                                  | 2 minutes                               | 1.8 hours.         |
| Contact point for OCSE Pre-offset notice  | 30                    | 1                                  | 1 minute                                | 0.9 hours.         |
| Non-TANF Tax Refund Offset Information    | 1,744                 | 40,735                             | 10 minutes                              | 6,789.2 hours.     |
| Offset notice address/phone number change | 54                    | 1                                  | 10 minutes                              | 9.0 hours.         |
| Personal computer data                    | 54                    | 1                                  | 5 minutes                               | 4.5 hours.         |
| Notice of intention                       | 25                    | 1                                  | 2 minutes                               | 0.8 hours.         |

Estimated Total Annual Burden Hours: 31,816.3.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW., Washington, DC 20503, Attn: Ms. Wendy Taylor.

Dated: October 28, 1997.

### **Bob Sargis**,

Acting Reports Clearance Officer.
[FR Doc. 97–28965 Filed 10–31–97; 8:45 am]
BILLING CODE 4184–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

Current Topics in Immunohematologic Testing; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

The Food and Drug Administration (FDA) is announcing a public workshop entitled "Current Topics in Immunohematologic Testing." The topics to be discussed include specificity and sensitivity of Anti-D Blood Grouping Reagents; the development of performance standards for antiglobulin control cells and blood bank saline; user interpretation of

labeling information; and the validation and use of blood grouping instrumentation.

Date and Time: The workshop will be held on December 10, 1997, 8 a.m. to 5 p.m.

Location: The workshop will be held at Natcher Auditorium, National Institutes of Health, 9000 Rockville Pike, Bldg. 45, Bethesda, MD.

Contact Person: Joseph Wilczek, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827– 3514, FAX 301–827–2843.

SUPPLEMENTARY INFORMATION: The goals of the workshop are specific to each topic and include the following: (1) Distinguish between those issues that are medically important and those issues that are primarily of scientific interest with respect to Anti-D specificity and sensitivity; (2) present examples of significant problems attributable to the variability seen within two types of product, antiglobulin control cells and blood bank saline, due to the lack of standards; (3) identify areas of immunohematologic product labeling which need to be modified to provide the user with a better understanding of its uses and limitations; and (4) discuss user validation of complete systems as well as partial or site-assembled systems regarding blood grouping instrumentation. The information obtained from these presentations and discussions will assist FDA in taking the necessary steps for assuring the safety and effectiveness of these medical

Registration and Requests for Oral Presentations: Send or fax registration information (including name, title, firm name, address, telephone, and fax number), written material, and requests to make oral presentations by November 28, 1997, to Cody Bridges, 14504 Greenview Dr., suite 500, Laurel, MD 20708, 301–490–5500, FAX 301–490–7260, e-mail CBRIDGES@lcgnet.com. Registration at the site will be done on

a space available basis on the day of the workshop beginning at 7:30 a.m. There is no registration fee for the workshop.

If you need special accommodations due to a disability, please contact Cody Bridges at least 7 days in advance.

Transcripts: Transcripts of the workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the workshop at a cost of 10 cents per page.

Dated: October 24, 1997.

#### William K. Hubbard.

Associate Commissioner for Policy Coordination.

[FR Doc. 97–29049 Filed 10–31–97; 8:45 am] BILLING CODE 4160–01–F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Health Care Financing Administration** 

[BPO-150-N]

Medicare and Medicaid Programs; Quarterly Listing of Program Issuances—First Quarter 1997

**AGENCY:** Health Care Financing Administration (HCFA), HHS.

**ACTION:** Notice.

SUMMARY: This notice lists HCFA manual instructions, substantive and interpretive regulations, and other Federal Register notices that were published during January, February, and March of 1997 that relate to the Medicare and Medicaid programs. It also identifies certain devices with investigational device exemption numbers approved by the Food and Drug Administration that may be potentially covered under Medicare.

Section 1871(c) of the Social Security Act requires that we publish a list of Medicare issuances in the **Federal Register** at least every 3 months. Although we are not mandated to do so